{
    "organizations": [],
    "uuid": "ad37b07de59cdaffd79c695bdbd5f70310037826",
    "author": "",
    "url": "https://www.reuters.com/article/brief-exelixis-says-ipsen-received-valid/brief-exelixis-says-ipsen-received-validation-of-the-application-for-variation-to-the-cabometyx-idUSFWN1R90YY",
    "ord_in_thread": 0,
    "title": "BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28, 2018 / 5:20 AM / Updated 4 minutes ago BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx Reuters Staff 1 Min Read March 28 (Reuters) - Exelixis Inc: * EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA * ‍FILING IS BASED ON RESULTS OF GLOBAL PIVOTAL PHASE 3 CELESTIAL TRIAL, WHICH MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS)​ * ‍CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS COMPARED WITH PLACEBO​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-03-28T08:15:00.000+03:00",
    "crawled": "2018-03-28T08:32:08.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "say",
        "ipsen",
        "received",
        "validation",
        "application",
        "variation",
        "cabometyx",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "exelixis",
        "inc",
        "exelixis",
        "partner",
        "ipsen",
        "announces",
        "ema",
        "validation",
        "application",
        "new",
        "indication",
        "cabozantinib",
        "previously",
        "treated",
        "advanced",
        "hepatocellular",
        "carcinoma",
        "based",
        "result",
        "global",
        "pivotal",
        "phase",
        "celestial",
        "trial",
        "met",
        "primary",
        "endpoint",
        "overall",
        "survival",
        "o",
        "provided",
        "statistically",
        "significant",
        "clinically",
        "meaningful",
        "improvement",
        "o",
        "compared",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}